CA3129722A1 - Crystalline forms of an rsk inhibitor - Google Patents

Crystalline forms of an rsk inhibitor Download PDF

Info

Publication number
CA3129722A1
CA3129722A1 CA3129722A CA3129722A CA3129722A1 CA 3129722 A1 CA3129722 A1 CA 3129722A1 CA 3129722 A CA3129722 A CA 3129722A CA 3129722 A CA3129722 A CA 3129722A CA 3129722 A1 CA3129722 A1 CA 3129722A1
Authority
CA
Canada
Prior art keywords
crystalline form
theta
compound
cancer
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129722A
Other languages
English (en)
French (fr)
Inventor
Richard WINNIKE
Elaine MCPHERSON
Erik Flahive
Sandra E. Dunn
Jonathan LOUGHREY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phoenix Molecular Designs Ltd
Original Assignee
Phoenix Molecular Designs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Molecular Designs Ltd filed Critical Phoenix Molecular Designs Ltd
Publication of CA3129722A1 publication Critical patent/CA3129722A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3129722A 2019-02-11 2020-02-10 Crystalline forms of an rsk inhibitor Pending CA3129722A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804076P 2019-02-11 2019-02-11
US62/804,076 2019-02-11
PCT/IB2020/000092 WO2020165646A1 (en) 2019-02-11 2020-02-10 Crystalline forms of an rsk inhibitor

Publications (1)

Publication Number Publication Date
CA3129722A1 true CA3129722A1 (en) 2020-08-20

Family

ID=72043971

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129722A Pending CA3129722A1 (en) 2019-02-11 2020-02-10 Crystalline forms of an rsk inhibitor

Country Status (9)

Country Link
US (1) US12378245B2 (https=)
EP (1) EP3924352A4 (https=)
JP (1) JP2022520382A (https=)
KR (1) KR20210126077A (https=)
CN (1) CN113677681A (https=)
AU (1) AU2020222056A1 (https=)
CA (1) CA3129722A1 (https=)
IL (1) IL285493A (https=)
WO (1) WO2020165646A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3129722A1 (en) 2019-02-11 2020-08-20 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor
CN117186098A (zh) * 2022-06-07 2023-12-08 上海科恩泰生物医药科技有限公司 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CA2268164A1 (en) 1996-10-08 1998-04-16 Yao-Chang Xu New serotonin 5-ht1f agonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
US6416780B1 (en) 1997-05-07 2002-07-09 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
WO2003087087A2 (en) 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
WO2007021795A2 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2690410C (en) 2007-06-12 2015-09-29 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
MX2010002732A (es) 2007-09-14 2010-06-02 Univ Michigan Inhibidores de f1f0-atpasa y metodos relacionados.
GB0718870D0 (en) 2007-09-27 2007-11-07 Univ Dundee Modulation of RSK
CN102573994B (zh) * 2009-08-06 2015-06-24 默克专利有限公司 双环脲化合物
WO2011071716A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
WO2011071725A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
CA2827609A1 (en) 2011-02-17 2012-11-15 Nestec S.A. Assays for detecting autoantibodies to anti-tnf.alpha. drugs
CA2913583C (en) 2012-06-04 2019-08-06 Phoenix Molecular Diagnostics Ltd. Methods of inhibiting rsk for treatment of breast cancer
CN103724251B (zh) 2014-01-18 2015-07-22 福州大学 一种靶向stat3的小分子化合物及其制备方法和应用
CA2944610C (en) 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
JP2018537486A (ja) * 2015-12-14 2018-12-20 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
MX376974B (es) * 2016-02-19 2025-03-07 Phoenix Molecular Designs Derivados de carboxamida útiles como inhibidores de rsk.
CA3129722A1 (en) 2019-02-11 2020-08-20 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor

Also Published As

Publication number Publication date
US20220112193A1 (en) 2022-04-14
KR20210126077A (ko) 2021-10-19
AU2020222056A1 (en) 2021-10-07
EP3924352A1 (en) 2021-12-22
IL285493A (en) 2021-09-30
JP2022520382A (ja) 2022-03-30
EP3924352A4 (en) 2022-11-16
US12378245B2 (en) 2025-08-05
WO2020165646A1 (en) 2020-08-20
CN113677681A (zh) 2021-11-19

Similar Documents

Publication Publication Date Title
US12378245B2 (en) Crystalline forms of an RSK inhibitor
ES2981114T3 (es) 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios
US10064866B2 (en) Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
UA114068C2 (xx) Кристалічні частинки (r)-3-(4-(2-(2-метилтетразол-5-іл)піридин-5-іл)-3-фторфеніл)-5-гідроксиметилоксазолідин-2-ондиводеньфосфату
US20190202840A1 (en) Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
EP3261631B1 (en) Inhibition of olig2 activity
US12145913B2 (en) Inhibition of Olig2 activity
US20200376004A1 (en) Amorphous onapristone compositions and methods of making the same
CN118139625A (zh) Wee1抑制剂和抗cd47抗体的组合
JP2024546584A (ja) Ｂｃｌ－２阻害剤、ｗｅｅ－１阻害剤及び他の化学療法剤の三剤療法の組み合わせ
CA3239205A1 (en) Combination therapy comprising an fgfr inhibitor and a kras inhibitor
JP7758369B2 (ja) Ｇａｓ４１阻害剤及びその使用方法
US20230117684A1 (en) Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
US20140275234A1 (en) Compositions and methods of using crystalline forms of wortmannin analogs
US20240116877A1 (en) Kit kinase inhibitors and methods of use thereof
WO2013070911A1 (en) Compounds and methods for treating cystic fibrosis
US20260098044A1 (en) Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1
CN104098575A (zh) 一种盐酸依匹斯汀晶型及其制备方法和用途
HK40008862A (en) Combination, application thereof and treatment method
BR122021024771B1 (pt) Uso de uma combinação de inibidores de jak1/2e pi3ksigma no tratamento de mielofibrose
BR112016023322B1 (pt) Uso de uma combinação de inibidores de jak e pi3ksigma

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260324